Pulmonary arteriovenous malformations emerge from the shadows

Shovlin CL\textsuperscript{12}, Condliffe R\textsuperscript{34}, Donaldson JW\textsuperscript{5}, Kiely DG\textsuperscript{34}, Wort SJ\textsuperscript{17}

Corresponding author:
Claire L. Shovlin, PhD, FRCP
Professor of Practice (Clinical and Molecular Medicine),
NHLI Vascular Science, Imperial College London,
Hammersmith Campus
Du Cane Road
London W12 0NN, UK
c.shovlin@imperial.ac.uk

Words: 1081
2 Figures
17 References

1 NHLI Vascular Science, Imperial College London, London UK
2 Respiratory Medicine, Imperial College Healthcare NHS Trust, London, UK
3 Pulmonary Vascular Disease Unit, Royal Hallamshire Hospital, Sheffield, UK
4 Department of Infection, Immunity and Cardiovascular Disease, University of Sheffield, Sheffield, UK
5 Royal Derby Hospital, Derby, UK
6 Pulmonary Hypertension Department, Royal Brompton Hospital, London, UK
7 NHLI Respiratory Science, Imperial College London, London UK
For many years, pulmonary arteriovenous malformations (PAVMs) have been an under-diagnosed and poorly understood aspect of respiratory medicine. Recent increases in the published literature have improved our understanding of their diagnosis and management. The BTS Clinical Statement on PAVMs published in the current issue of Thorax aims to drive an improvement in the care provided to this often-neglected patient group.[1] The statement is the first example of a new method of summarising data and providing an expert view of best practice in a given clinical area.

Three major issues are associated with poor health outcomes in patients with PAVMs: lack of clinician awareness and education, an absence of standardised approaches to patient management, and an urgent need for service development for a condition estimated to affect more than 10,000 people in the UK.[2]

1) Clinician Awareness and Education:

PAVMs are under-represented in medical school syllabuses and, more importantly, not mentioned in UK or US specialist respiratory training curriculae.[3] These abnormal blood vessels connect pulmonary arteries directly to pulmonary veins, allowing a proportion of systemic venous blood to bypass the pulmonary capillary bed and return ‘unprocessed’ to the left heart and systemic arterial tree (Fig. 1). Although shunting via PAVMs impairs gas exchange, patients usually compensate very well for hypoxaemia and the exuberant ventilatory requirements by physiological mechanisms such as secondary erythrocytosis and changes in haemodynamics to maintain normal oxygen delivery (Fig. 2). In contrast, there are no compensatory mechanisms that enable restoration of the pulmonary capillary “filter” to prevent paradoxical emboli[4](Fig. 2).

In the UK, PAVM complication rates remain particularly high:[5]: 6% cerebral abscess[6] 12% ischemic stroke[7], and 1% maternal death in pregnancy[8]. It is of concern that this may be partly driven by poor appreciation of the condition - one recent UK study found the mean delay from diagnosis to referral for treatment was 7.5 years. [9] Conversely, a lack of experience with the condition can lead to patients
receiving inaccurate or misleading counsel regarding complication risks (e.g. overestimating bleeding risk), which can cause unnecessary alarm.

Hereditary haemorrhagic telangiectasia (HHT) is found in most patients with PAVMs. Only if the PAVM is single should a sporadic aetiology be considered; even then, a single PAVM is most likely to be due to HHT. HHT is a multisystemic vascular disorder, inherited as an autosomal dominant trait, and usually caused by a pathogenic gene variant ("mutation") in ENG, ACVRL1, or SMAD4. [10] Almost all individuals with HHT experience recurrent nosebleeds due to nasal telangiectasia, and these can frequently lead to iron deficiency and anaemia, sometimes enhanced by blood loss from gastrointestinal telangiectasia.[11] Approximately 50% of HHT patients have PAVMs, similar proportions have hepatic AVMs, and 10% are estimated to have cerebral AVMs. A high clinical index of suspicion for HHT/PAVMs is crucial to case ascertainment - despite this, HHT passes unmentioned in many formal clinician training programmes. At least one European country has initiated programmes that have normalised life-expectancy in HHT.[12] However, across the UK, barely 10% of the expected number of HHT cases are seen in specialist centres, and life expectancy is estimated to be reduced by two years implying that complication rates are likely to be higher [13].

2) Standardised Approach to Clinical Management

This British Thoracic Society Clinical Statement [1] addresses PAVM management from basic principles through state-of-the-art evidence-based updates to earlier clinical guidance. Key points include:

- It is critical that individuals with PAVMs are referred to services capable of providing comprehensive counselling and care, given the evidence that the major complications of PAVMs can be prevented and general lifestyle and supportive therapy can improve patient outcomes.
- Embolization remains the mainstay of interventional treatment, but the prevention of major complications is also aided by general measures that need to be followed throughout the life of the patient. An important example is the use of antibiotic prophylaxis prior to dental procedures.[14]
• The risk-benefit profile and the cost of various follow-up approaches must also be carefully considered. For example, there has been a move away from protocolised CT scan follow-up in view of cumulative radiation dosages.[15]

• Patients with HHT should be screened for PAVMs. Family members of PAVM and/or HHT patients should be screened for HHT and PAVMs. When performing PAVM screening, a normal chest x-ray and oxygen saturations are not sufficient to exclude PAVMs and either a normal thoracic CT scan or normal contrast echocardiogram are required.

3) Service Development

The third, and arguably most challenging area to address, is how to develop an appropriately supported service throughout the UK able to meet one of the aims of the NHS in giving equitable and timely access to high quality care for all patients. For example, the largest UK PAVM service has managed more than 800 PAVM patients, and more than 400 HHT families since its inception in 1985. Referrals now exceed 300 cases per annum, but the Consultant-led service receives no specific commissioning support. Services in smaller PAVM/HHT centres in other parts of the country are also delivered by clinicians without specific commissioning support.

Within the NHS, there is a lack of recognition of the long-term and complex nature of care that these patients require. PAVMs and HHT may be perceived as too common for specialist service commissioning, but service hubs are too infrequent for commissioning to be addressed regionally. Delivery of good clinical care requires robust links between locally-based and specialist care. In turn, in light of the multi-system nature of HHT, specialist centres need to be embedded within a clinical network encompassing multiple medical and surgical specialities.

Encouragingly, there are indicators that PAVMs are finally receiving the necessary attention that may lead to such systems being realised. The European Commission has led the way in establishing the European
Reference Network for Rare Multisystemic Vascular Diseases (VASCERN). VASCERN is a natural home for PAVMs and HHT, although currently includes only one UK PAVM/HHT service. The patient pathways recommended by VASCERN are based on intermittent review of patients in specialist centres, with those centres supporting local and primary care providers of long-term care. In addition, NHS England’s new gene test commissioning pathways for mainstream clinicians should help guide familial management in conditions such as PAVMs and HHT which may be difficult to diagnose clinically. Finally, it is hoped that the championing of the condition by the British Thoracic Society and the provision of this Clinical Statement will influence the NHS to adequately finance the service that patients with PAVMs and HHT deserve.

In summary, we hope that this Clinical Statement will shine a spotlight on this under-appreciated condition and bring PAVMs out of the shadows.
REFERENCES


16 European Reference Network for Rare Multisystemic Vascular Diseases (VASCERN) 

17 European Reference Network for hereditary haemorrhagic telangiectasia (VASCERN HHT) 
FIGURE LEGENDS:

Figure 1: The impact of PAVMs on the circulation:

A pulmonary arteriovenous malformation provides an anatomic right-to-left shunt, allowing unprocessed pulmonary arterial blood to enter the systemic circulation.

Figure 2: PAVM pathophysiology.

Slower compensatory processes on the left side of the diagram contrast with ‘critical events’ of decompensation on the right.